Pheno.AI’s Human Phenotype Project (HPP) to Catalyze the Future of AI-Driven Health with Japanese Cohort
TOKYO, March 26, 2025 /PRNewswire/ — Corundum Systems Biology Inc. (CSB), a leading investment company dedicated to advancing life-changing systems biology solutions for human health and well-being, today announced it is supporting Israeli AI-driven health startup Pheno.AI‘s launch in Japan. The initiative will facilitate the eventual global expansion of Pheno.AI’s Human Phenotype Project (HPP).
CSB, an early investor in Pheno.AI since the startup launched in 2022, is providing strategic support and resources to accelerate the deployment of the HPP initiative in Japan. HPP is a large-scale deep-phenotyping project leveraging AI to derive critical insights from human health data across diverse global populations. It aims to facilitate the development of groundbreaking solutions that improve global human health and well-being.
“The launch of Pheno.AI Japan marks a pivotal step in the HPP initiative’s global expansion and will generate a comprehensive dataset from thousands of Japanese participants,” said Hidehiko Otake, CEO of Corundum Systems Biology. “This dataset will contribute to a global AI-powered health innovation framework designed to advance medical research and improve healthcare outcomes worldwide.”
The Human Phenotype Project is a landmark global effort to empower scientists researching the next breakthroughs in human health. Profiling a diverse participant base of individuals, and incorporating a rich set of data layers and environmental influences, it is building a high-resolution view of the key drivers behind health and disease to impact the way we approach and treat a wide range of conditions. HPP’s proprietary datasets are already yielding insights that are helping to advance science and innovation across the pharmaceutical, healthcare, and life sciences industries.
“CSB has been instrumental in supporting Pheno.AI through financial investment, strategic advisory, and resource allocation,” said Prof. Eran Segal, PhD, Co-founder of Pheno.AI. “Our partnership with CSB to establish Pheno.AI Japan as a dedicated subsidiary provides a bridge between Pheno.AI and Japanese corporate stakeholders, fostering collaborations within the local healthcare ecosystem that can drive innovation to address global health challenges.”
About Corundum Systems Biology
Corundum Systems Biology (CSB) is dedicated to advancing breakthroughs in human health and well-being by supporting groundbreaking companies in the field of systems biology. Committed to the long-term success and impact of its portfolio companies, Corundum Systems Biology offers deep domain expertise, connections to a broad network of industry and scientific leaders, and access to unique sources of health data. For company updates and information, follow Corundum Systems Biology on LinkedIn or visit: https://www.csb.co.jp.
Media Contact
Danny Sudwarts
FINN Partners for Corundum
danny.sudwarts@finnpartners.com
SOURCE Corundum Systems Biology
The world's first modular exoskeleton combines quasi-direct-drive hip and cable-drive knee technologies for natural, powerful…
Leveraging Medical Robotics Heritage, the Company Expands into Consumer Market, Envisioning Exoskeletons as Integral 'New…
The consolidated entity will leverage AI and precision engineering to create a comprehensive ecosystem advancing…
MESA, Ariz., Jan. 9, 2026 /PRNewswire/ -- Gifthealth, a unified digital pharmacy platform, today celebrated the…
NASHVILLE, Tenn., Jan. 9, 2026 /PRNewswire/ -- Today, Lucent Health, one of the nation's largest independent…